Skip to main content

Comment on: “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review”

The Original Article was published on 17 July 2018

This is a preview of subscription content, access via your institution.


  1. Vondeling GT, Cao Q, Postma MJ, Rozenbaum MH. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16(5):653–60.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chaves GC, Oliveira MA, Hasenclever L, de Melo LM. Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines. Cad Saude Publica. 2007;23(2):257–67.

    Article  PubMed  Google Scholar 

  3. World Health Organization. Medicine availability of selected generic medicines. 2015.

  4. Diependaele L, Cockbain J, Sterckx S. Raising the barriers to access to medicines in the developing world—the relentless push for data exclusivity. Dev World Bioeth. 2017;17(1):11–21.

    Article  PubMed  Google Scholar 

  5. Hug SE, Brändle MP. The coverage of Microsoft Academic: analyzing the publication output of a university. Scientometrics. 2017;113(3):1551–71.

    Article  Google Scholar 

  6. Thelwall M. Microsoft Academic: a multidisciplinary comparison of citation counts with Scopus and Mendeley for 29 journals. J Informetr. 2017;11(4):1201–12.

    Article  Google Scholar 

  7. Haunschild R, Hug SE, Brändle MP, Bornmann L. The number of linked references of publications in Microsoft Academic in comparison with the web of science. Scientometrics. 2018;114(1):367–70.

    Article  Google Scholar 

  8. Punjabi SS, Johnsrud MT, Conner C. Economic impact of Prozac® patent expiration and the 180-day generic fluoxetine exclusivity in a publicly-financed prescription program. Val Health. 2003;6(3):192.

    Article  Google Scholar 

  9. Keele MG, Butkow N, Venter D. Beyond patent expiry: development of a model for pricing generic drugs in South Africa. Val Health. 2013;16(7):A466.

    Article  Google Scholar 

  10. Riku J. Current situation for generic drugs in Japan. J Generic Medicines. 2005;2(3):219–31.

    Article  Google Scholar 

  11. Oh KY, Kim B, Kim T. Estimating market share function of generic drugs after patent expiration in Korea. Kor J Health Econ Policy. 2007;13(1):117–38.

    Google Scholar 

  12. Adriaen M, De Witte K, Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. J Generic Med. 2008;5(3):175–87.

    Article  Google Scholar 

  13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Carlos Vílchez-Román.

Ethics declarations

Conflict of Interest

We, Carlos Vílchez-Román, Sol Sanguinetti and Edward Mezones-Holguín declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article. For this article, Carlos Vílchez-Román received funding from CENTRUM Católica Graduate Business School (CCGBS), and Sol Sanguinetti received funding from Universidad de Lima (ULima).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vílchez-Román, C., Sanguinetti, S. & Mezones-Holguín, E. Comment on: “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review”. Appl Health Econ Health Policy 17, 255–256 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI: